TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
Completed
Children's Cancer and Leukaemia Group
Phase 3
2001-06-01
RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in
children with non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for
children who have non-Hodgkin's lymphoma.
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
Completed
National Cancer Institute (NCI)
Phase 3
2001-06-01
RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in
children with non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for
children who have non-Hodgkin's lymphoma.
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
Completed
Societe Francaise Oncologie Pediatrique
Phase 3
2001-06-01
RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in
children with non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for
children who have non-Hodgkin's lymphoma.
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
Completed
Children's Oncology Group
Phase 3
2001-06-01
RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in
children with non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for
children who have non-Hodgkin's lymphoma.
Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Completed
National Cancer Institute (NCI)
Phase 2
1997-08-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating
patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did
not achieve first remission.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
